HYPR

Hyperfine, Inc. Class A Common Stock (HYPR) | Rumor.io

Hyperfine

HYPR

Attention (50-day avg)0%

Attention rank (50-day avg)#2,672

Bullish sentiment (50-day avg)89%

Price to earnings ratio-1.96

Market capitalization88.7M

Earnings per share-0.37

Dividend yield (TTM)—

Revenue (annual)13.6M

Net income (annual)-35.6M

Social

What share of all stock conversation is about HYPR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 25

Hyperfine (HYPR) is gaining attention for its portable MRI technology, with some investors speculating it could become an acquisition target.
The company's stock, HYPR, has seen a significant volume spike, potentially indicating a breakout.
There is a formula that claims to accurately predict the daily stock price change of HYPR relative to the HYPE.X token.

Generated by AI

Sentiment

Of the messages about HYPR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	27.27% -72.73	73.33% -23.54	85.54% -4.91
Bearish	—	72.73% +72.73	26.67% +23.54	14.46% +4.91

Bullish· Oct 8

$HYPR has shown insane volume lately, indicating strong market interest.
The company's Swoop MRI technology is a game-changer, with potential for additional indications in the future.
$HYPR is still undervalued and has the potential to go global, with a possible 10x return from current levels.

Bearish· Jun 2

$HYPR's price action suggests it's due for a significant correction, with some analysts predicting a drop to new lows.
The company's enterprise value of $14 million is considered overly optimistic, especially given its FDA-clearance status and 200% growth potential.
Despite two recent FDA 510k approvals, $HYPR's price is trading near its 52-week low, indicating a potential reversal in investor sentiment.

Generated by AI

Topics

Of the messages about HYPR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	64.95%
Technical Analysis	—	—	0%	17.08%
Earnings	—	—	0%	3.18%
Analysts	—	—	0%	6.16%
Controversies	—	—	0%	1.29%
Macro	—	—	0%	7.35%

Jun 2

Hyperfine, Inc. ($HYPR) announces FDA clearance of a new next-generation Swoop system powered by Optive AI software, delivering a transformative leap in image quality.
The new Swoop system combines powerful AI with a reimagined portable MRI platform, enabling brain imaging to be delivered in a wide range of care environments, including critical care, emergency, and clinic settings.
The FDA clearance is a significant milestone for Hyperfine, with the company's technology potentially transforming the hospital system as we know it, and with over 500 patents and real-world adoption already underway.

Generated by AI

Community

Of the messages about HYPR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	73.33%	79.03%	46.34%
Newcomers	—	26.67%	20.97%	53.66%

Regulars· Nov 20

Hyperfine, Inc. ($HYPR) has received a $3.7M grant to advance global brain health initiatives, leveraging its technology in partnership with NVDA.
The grant will enable Hyperfine to accelerate the development of its MRI technology and expand its global reach, with a focus on improving brain health outcomes.
Regular participants in the HYPR discussion emphasize the significance of this grant in propelling Hyperfine's mission forward and its potential impact on the field of brain health research.

Newcomers· Mar 18

The loan agreement is a $40 million term loan facility with Horizon Technology Finance, with an initial draw of $15 million and an additional $25 million available through December 2027.
Hyperfine's Q4 2025 results show a 128% revenue growth year-over-year, with a revenue of $5.29 million, and a FY 2025 revenue of $13.56 million.
The loan facility and strong Q4 2025 results are expected to drive options flow and potentially impact the stock's price, with active buyers and traders positioning for a move.

Generated by AI

News

Hyperfine appoints distributor for Kuwait and UAE markets

1d agoInvesting.com

Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets

GUILFORD, Conn., September 28, 2026--Hyperfine appoints Roots Pharmaceutical as exclusive Swoop system distributor in the United Arab Emirates and Kuwait.

1d agoYahoo Finance

Hyperfine, Inc. (HYPR) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow (NASDAQ:HYPR) 2026-06-05

7d agoSeeking Alpha

MedtechWOMEN Names Hyperfine CEO Maria Sainz Winner of 2026 Ferolyn Powell Leadership Award

MENLO PARK, Calif., September 16, 2026--MedtechWOMEN today announced that Maria Sainz, President and CEO of Hyperfine, Inc., has been named the recipient of its 2026 Ferolyn Powell Leadership Award, and that Beverly Tang, co-founder and CEO of Starlight Cardiovascular, has received MedtechWOMEN’s first-ever Rising Star Award. Both leaders were recognized at the annual MedtechVISION Annual Conference at the Rosewood Sand Hill in Menlo Park, Calif.

13d agoYahoo Finance

Hyperfine completes enrollment in contrast MRI study

15d agoInvesting.com

Hyperfine stock maintains buy rating at BTIG on AI software update

16d agoInvesting.com

Also Discussed

Investors talking about HYPR also mention

#	Name	Attention
1	Quantum-Si Incorporated Class A Common StockQSI	0.02%+0.02
2	Butterfly Network, Inc.BFLY	0.01%0
3	GRAY - Graybug Vision, Inc.	——
4	Movado Group, Inc.MOV	0%0
5	Design Therapeutics, Inc.DSGN	0%0
6	CRA International, Inc.CRAI	0%new
7	MESSIERM87	0.01%+0
8	AMPD - CNIC ICE U.S. Carbon Neutral Power Futures Index ETF	——
9	First Trust Bloomberg Artificial Intelligence ETFFAI	0%new
10	Invesco High Income Trust IIVLT	0%0

Hyperfine, Inc. Class A Common Stock

Healthcare
Medical Devices

Hyperfine, Inc. Class A Common Stock represents the equity of Hyperfine, Inc., a health technology and medical device company focused on portable magnetic resonance imaging. The company develops and commercializes the Swoop portable MR imaging system, which is designed to support brain imaging and clinical monitoring in settings where traditional MRI systems are less practical. Hyperfine also provides related support, maintenance, and technical services tied to its imaging products. Its offerings serve hospitals, intensive care units, stroke centers, and other medical facilities that use portable neuroimaging to help broaden access to diagnostic imaging. Based in Guilford, Connecticut, Hyperfine operates in the medical specialties segment of the health technology market, where it combines imaging hardware, software, and service capabilities around ultra-low-field MRI applications.

Website

Location

351 New Whitfield Street

Guilford, CT, 06437

United States

Social

What share of all stock conversation is about HYPR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 25

Hyperfine (HYPR) is gaining attention for its portable MRI technology, with some investors speculating it could become an acquisition target.
The company's stock, HYPR, has seen a significant volume spike, potentially indicating a breakout.
There is a formula that claims to accurately predict the daily stock price change of HYPR relative to the HYPE.X token.

Generated by AI

Sentiment

Of the messages about HYPR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	27.27% -72.73	73.33% -23.54	85.54% -4.91
Bearish	—	72.73% +72.73	26.67% +23.54	14.46% +4.91

Bullish· Oct 8

$HYPR has shown insane volume lately, indicating strong market interest.
The company's Swoop MRI technology is a game-changer, with potential for additional indications in the future.
$HYPR is still undervalued and has the potential to go global, with a possible 10x return from current levels.

Bearish· Jun 2

$HYPR's price action suggests it's due for a significant correction, with some analysts predicting a drop to new lows.
The company's enterprise value of $14 million is considered overly optimistic, especially given its FDA-clearance status and 200% growth potential.
Despite two recent FDA 510k approvals, $HYPR's price is trading near its 52-week low, indicating a potential reversal in investor sentiment.

Generated by AI

Topics

Of the messages about HYPR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	64.95%
Technical Analysis	—	—	0%	17.08%
Earnings	—	—	0%	3.18%
Analysts	—	—	0%	6.16%
Controversies	—	—	0%	1.29%
Macro	—	—	0%	7.35%

Jun 2

Hyperfine, Inc. ($HYPR) announces FDA clearance of a new next-generation Swoop system powered by Optive AI software, delivering a transformative leap in image quality.
The new Swoop system combines powerful AI with a reimagined portable MRI platform, enabling brain imaging to be delivered in a wide range of care environments, including critical care, emergency, and clinic settings.
The FDA clearance is a significant milestone for Hyperfine, with the company's technology potentially transforming the hospital system as we know it, and with over 500 patents and real-world adoption already underway.

Generated by AI

Community

Of the messages about HYPR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	73.33%	79.03%	46.34%
Newcomers	—	26.67%	20.97%	53.66%

Regulars· Nov 20

Hyperfine, Inc. ($HYPR) has received a $3.7M grant to advance global brain health initiatives, leveraging its technology in partnership with NVDA.
The grant will enable Hyperfine to accelerate the development of its MRI technology and expand its global reach, with a focus on improving brain health outcomes.
Regular participants in the HYPR discussion emphasize the significance of this grant in propelling Hyperfine's mission forward and its potential impact on the field of brain health research.

Newcomers· Mar 18

The loan agreement is a $40 million term loan facility with Horizon Technology Finance, with an initial draw of $15 million and an additional $25 million available through December 2027.
Hyperfine's Q4 2025 results show a 128% revenue growth year-over-year, with a revenue of $5.29 million, and a FY 2025 revenue of $13.56 million.
The loan facility and strong Q4 2025 results are expected to drive options flow and potentially impact the stock's price, with active buyers and traders positioning for a move.

Generated by AI

Hyperfine

Social

Jun 25

Bullish· Oct 8

Bearish· Jun 2

Jun 2

Regulars· Nov 20

Newcomers· Mar 18

Hyperfine appoints distributor for Kuwait and UAE markets

Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets

Hyperfine, Inc. (HYPR) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow (NASDAQ:HYPR) 2026-06-05

MedtechWOMEN Names Hyperfine CEO Maria Sainz Winner of 2026 Ferolyn Powell Leadership Award

Hyperfine completes enrollment in contrast MRI study

Hyperfine stock maintains buy rating at BTIG on AI software update

Also Discussed

Hyperfine, Inc. Class A Common Stock

Company Information

Location

Hyperfine appoints distributor for Kuwait and UAE markets

Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets

Hyperfine, Inc. (HYPR) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow (NASDAQ:HYPR) 2026-06-05

MedtechWOMEN Names Hyperfine CEO Maria Sainz Winner of 2026 Ferolyn Powell Leadership Award

Hyperfine completes enrollment in contrast MRI study

Hyperfine stock maintains buy rating at BTIG on AI software update

Also Discussed

Social

Jun 25

Bullish· Oct 8

Bearish· Jun 2

Jun 2

Regulars· Nov 20

Newcomers· Mar 18